Willan AR - Search Results

1

Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate.

Willan AR, Kowgier ME. Willan AR, et al. Health Econ. 2008 Jul;17(7):777-91. doi: 10.1002/hec.1289. Health Econ. 2008. PMID: 17764096

2

Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.

Willan AR, O'Brien BJ. Willan AR, et al. Health Econ. 1999 May;8(3):203-11. doi: 10.1002/(sici)1099-1050(199905)8:3<203::aid-hec413>3.0.co;2-7. Health Econ. 1999. PMID: 10348415

3

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.

Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM. Nicholson A, et al. Among authors: willan ar. Haemophilia. 2008 Jan;14(1):127-32. doi: 10.1111/j.1365-2516.2007.01562.x. Epub 2007 Nov 13. Haemophilia. 2008. PMID: 18005148

4

Expected Value of Sample Information with Imperfect Implementation: Improving Practice and Reducing Uncertainty with Appropriate Counterfactual Consideration.

Eckermann S, Willan AR. Eckermann S, et al. Among authors: willan ar. Med Decis Making. 2016 Apr;36(3):282-3. doi: 10.1177/0272989X16635130. Med Decis Making. 2016. PMID: 26929164 No abstract available.

5

Value of information and pricing new healthcare interventions.

Willan AR, Eckermann S. Willan AR, et al. Pharmacoeconomics. 2012 Jun 1;30(6):447-59. doi: 10.2165/11592250-000000000-00000. Pharmacoeconomics. 2012. PMID: 22591129

6

Optimal clinical trial design using value of information methods with imperfect implementation.

Willan AR, Eckermann S. Willan AR, et al. Health Econ. 2010 May;19(5):549-61. doi: 10.1002/hec.1493. Health Econ. 2010. PMID: 19399753

7

Value of information methods for assessing a new diagnostic test.

Chen MH, Willan AR. Chen MH, et al. Among authors: willan ar. Stat Med. 2014 May 20;33(11):1801-15. doi: 10.1002/sim.6085. Epub 2014 Jan 9. Stat Med. 2014. PMID: 24403241

8

Response times follow lognormal or gamma distribution in arthritis patients.

Abrahamyan L, Beyene J, Feng J, Chon Y, Willan AR, Schmeling H, Horneff G, Keystone EC, Feldman BM. Abrahamyan L, et al. Among authors: willan ar. J Clin Epidemiol. 2010 Dec;63(12):1363-9. doi: 10.1016/j.jclinepi.2009.11.019. J Clin Epidemiol. 2010. PMID: 20430577 Clinical Trial.

9

Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials.

Abrahamyan L, Li CS, Beyene J, Willan AR, Feldman BM. Abrahamyan L, et al. Among authors: willan ar. J Clin Epidemiol. 2011 Mar;64(3):286-92. doi: 10.1016/j.jclinepi.2010.02.021. Epub 2010 Oct 6. J Clin Epidemiol. 2011. PMID: 20926258

10

Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.

Willan AR, Goeree R, Pullenayegum EM, McBurney C, Blackhouse G. Willan AR, et al. Pharmacoeconomics. 2006;24(1):93-106. doi: 10.2165/00019053-200624010-00008. Pharmacoeconomics. 2006. PMID: 16445306

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results